Revenue and Profitability - Revenue increased by 12.4% to RMB 7,151.0 million (2021: RMB 6,359.8 million) [2] - Profit attributable to equity holders of the parent increased by RMB 486.3 million or 202.0% to RMB 727.1 million [2] - Net profit attributable to equity holders increased by 202.0% to RMB 727.1 million, with basic earnings per share rising to RMB 0.50 from RMB 0.16 in 2021 [11] - Gross profit was RMB 2,290.2 million (2021: RMB 1,993.6 million), with a gross margin of 32.0%, up 0.7 percentage points [2] - Gross profit increased by RMB 296.6 million to RMB 2,290.2 million, compared to RMB 1,993.6 million in the same period last year, with a gross margin rise from 31.3% to 32.0% [38] Business Segments Performance - Formulation business sales revenue grew by 21.7% to RMB 3,210.5 million (2021: RMB 2,638.2 million) [2] - CDMO business sales revenue increased by 33.3% to RMB 1,084.1 million (2021: RMB 813.1 million) [2] - The pharmaceutical formulation segment achieved a revenue growth of 21.7%, totaling approximately RMB 3,210.5 million, accounting for 44.9% of total revenue [15] - CDMO services revenue grew by 33.3% to RMB 1,084.1 million, indicating strong demand in this segment [13] - The API business generated approximately RMB 2,673.8 million in sales revenue, accounting for 37.4% of total revenue, with a gross margin improvement to 27.7% [19] Market Expansion and Strategy - The company has established exclusive development and commercialization rights for several innovative drug candidates in Greater China, focusing on immune-related diseases [10] - The supply chain strategy has been enhanced to ensure material supply and operational efficiency amid global economic challenges [10] - The company is actively developing proprietary drug candidates currently in the preclinical stage [10] - The company actively expanded its market presence in France and Switzerland, further solidifying its position in Europe [16] - The company achieved significant sales growth in emerging markets such as Malaysia, Brazil, and Saudi Arabia, while also advancing international drug registration efforts [17] Financial Position and Assets - Total assets less current liabilities amounted to RMB 15,238.4 million (2021: RMB 14,316.7 million) [7] - Net assets attributable to equity holders of the parent increased to RMB 12,310.9 million (2021: RMB 11,411.4 million) [7] - Total assets as of December 31, 2022, were approximately RMB 20,814.2 million, compared to RMB 19,108.2 million as of December 31, 2021 [46] - Total liabilities as of December 31, 2022, were approximately RMB 8,406.6 million, compared to RMB 7,584.9 million as of December 31, 2021, resulting in a debt-to-asset ratio of approximately 40.4% [46] Dividends and Shareholder Returns - The board declared a final cash dividend of RMB 1.0 per ordinary share (tax included) for the year [2] - The proposed final dividend per ordinary share for 2022 is RMB 0.10, compared to RMB 0.035 in 2021, representing an increase of 185.7% [77] - The final dividend will be distributed to H shareholders no later than August 15, 2023, if approved [87] - The annual general meeting is scheduled for May 22, 2023, where the dividend proposal will be discussed [88] Research and Development - The AR-301 monoclonal antibody is currently in global Phase III clinical trials, with 174 subjects enrolled, showing promising results in reducing mechanical ventilation time for patients with ventilator-associated pneumonia [24] - Oregovomab's Phase II clinical trial demonstrated a median progression-free survival (PFS) of 41.8 months compared to 12.2 months for the control group, with a hazard ratio (HR) of 0.46 [25] - RVX-208 has completed Phase III trials and received FDA breakthrough therapy designation, aiming to reduce major adverse cardiovascular events in high-risk patients [27] - H1710, an acetyl heparinase inhibitor, has completed active pharmaceutical ingredient production and is preparing for IND application in both China and the US [28] Operational Efficiency and Cost Management - The sales cost increased by RMB 494.7 million to RMB 4,860.9 million, primarily due to rising costs in pharmaceutical formulations and CDMO services [35] - Financing costs rose by RMB 35.5 million to RMB 245.6 million, an increase of 16.9% compared to RMB 210.1 million in the same period last year [39] - The company aims to enhance global supply chain management and digital integration to improve operational efficiency and resilience [29] Compliance and Governance - The audit committee reviewed the consolidated annual performance for the year ended December 31, 2022, and confirmed compliance with relevant accounting standards [92] - The company's auditor confirmed that the financial figures in the performance announcement are consistent with the consolidated financial statements [93] - There are no post-reporting period matters requiring shareholder attention [94]
海普瑞(09989) - 2022 - 年度业绩